Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay K Gopal

Showing results (21-30 of 186) with videos related to

Pageof 19
Sort By:
Cancer Investigation|February 8, 2025
Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024Daniel J Olivieri, Ajay K Gopal, Thomas S Uldrick, et al.
Blood Research|May 13, 2022
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8<sup>+</sup> T-cells despite immune checkpoint signalingAdam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, et al.
Leukemia & Lymphoma|May 15, 2024
Mitigating time toxicity in lymphoma and multiple myelomaMengyang Di, Christopher T Su, Andrew J Cowan, et al.
Blood|April 1, 2009
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphomaAjay K Gopal, John M Pagel, Jonathan R Fromm, et al.
Cancer Genetics|March 23, 2024
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expressionChia-Chen Ho, Kikkeri Naresh, Yajuan Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 6, 2026
HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer CenterC Natasha Kwendakwema, Kristine F Lan, H Nina Kim, et al.
Blood|May 27, 2008
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbAjay K Gopal, Oliver W Press, Shani M Wilbur, et al.
Leukemia & Lymphoma|October 25, 2008
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphomaRenata Zaucha, Ted Gooley, Leona Holmberg, et al.
Journal of Clinical Apheresis|February 3, 2012
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cellsAjay K Gopal, Mehdi Karami, JoAl Mayor, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphomaRyan D Cassaday, Andre Goy, Suresh Advani, et al.
Pageof 19

Showing results (21-30 of 186) with videos related to

Sort By:
Pageof 19
Cancer Investigation|February 8, 2025
Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024Daniel J Olivieri, Ajay K Gopal, Thomas S Uldrick, et al.
Blood Research|May 13, 2022
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8<sup>+</sup> T-cells despite immune checkpoint signalingAdam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, et al.
Leukemia & Lymphoma|May 15, 2024
Mitigating time toxicity in lymphoma and multiple myelomaMengyang Di, Christopher T Su, Andrew J Cowan, et al.
Blood|April 1, 2009
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphomaAjay K Gopal, John M Pagel, Jonathan R Fromm, et al.
Cancer Genetics|March 23, 2024
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expressionChia-Chen Ho, Kikkeri Naresh, Yajuan Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 6, 2026
HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer CenterC Natasha Kwendakwema, Kristine F Lan, H Nina Kim, et al.
Blood|May 27, 2008
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbAjay K Gopal, Oliver W Press, Shani M Wilbur, et al.
Leukemia & Lymphoma|October 25, 2008
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphomaRenata Zaucha, Ted Gooley, Leona Holmberg, et al.
Journal of Clinical Apheresis|February 3, 2012
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cellsAjay K Gopal, Mehdi Karami, JoAl Mayor, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphomaRyan D Cassaday, Andre Goy, Suresh Advani, et al.
Pageof 19